A proposed class action lawsuit commenced against a New Brunswick medical cannabis production company alleging the company used unapproved pesticides. The company, unfortunately named Organigram, has used certified organic labels to sell its cannabis products to medical users. Testing Organigram’s oil and dried product, Canada’s national department for public health, fortunately named Health Canada, discovered various products contained myclobutanil and bifenazate. Neither substance has a place on the list of thirteen approved pesticides for use on cannabis in Canada. Specifically, the filing states that the positive tests proved that the products purchased failed to meet organic guidelines as advertised. However, the case’s proposed class representative also suffered nausea and vomiting for six months while using the product, which subsided a month after ceasing use, facts that could expose the company to damages for bodily injuries as well.
Since the lawsuit’s announcement, Organigram has scrambled to pacify former customers. The company announced it shuffled CEOs and that a supposedly extensive investigation failed to find the contamination’s source. Attempting to mitigate potential other claimants, Organigram offered a full credit towards future purchases while setting aside $2.26 million to cover potential losses.
In an industry growing at such an amazing rate, companies like Organigram are potentially hindering the health and safety related missions other companies strive toward. Uncertainty and mislabeling only serve to cast doubt on medicine people deserve access to. While other industries may scrape by with a refund offer, the potential health effects that may slowly appear in Organigram’s customers will complicate matters. With a class action that may have upwards of 2000 plaintiffs, the meager losses set aside ($2.26 million) ignore potential injury.